ATE165359T1 - Imidderivate, ihre herstellung und verwendung - Google Patents

Imidderivate, ihre herstellung und verwendung

Info

Publication number
ATE165359T1
ATE165359T1 AT91111223T AT91111223T ATE165359T1 AT E165359 T1 ATE165359 T1 AT E165359T1 AT 91111223 T AT91111223 T AT 91111223T AT 91111223 T AT91111223 T AT 91111223T AT E165359 T1 ATE165359 T1 AT E165359T1
Authority
AT
Austria
Prior art keywords
group
aromatic
hydrocarbon ring
aromatic hydrocarbon
chem
Prior art date
Application number
AT91111223T
Other languages
English (en)
Inventor
Ikutaro Saji
Masayuki Muto
Norihiko Tanno
Mayumi Yoshigi
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16080314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE165359(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE165359T1 publication Critical patent/ATE165359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
AT91111223T 1990-07-06 1991-07-05 Imidderivate, ihre herstellung und verwendung ATE165359T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18027190 1990-07-06

Publications (1)

Publication Number Publication Date
ATE165359T1 true ATE165359T1 (de) 1998-05-15

Family

ID=16080314

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91111223T ATE165359T1 (de) 1990-07-06 1991-07-05 Imidderivate, ihre herstellung und verwendung

Country Status (9)

Country Link
US (2) US5532372A (de)
EP (1) EP0464846B1 (de)
JP (1) JP2800953B2 (de)
AT (1) ATE165359T1 (de)
CA (1) CA2046429C (de)
DE (2) DE69129282T4 (de)
DK (1) DK0464846T3 (de)
ES (1) ES2115599T3 (de)
GR (1) GR3026697T3 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5561128A (en) * 1989-05-19 1996-10-01 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-piperidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility
GB9202915D0 (en) * 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
TW421649B (en) * 1995-01-31 2001-02-11 Janssen Pharmaceutica Nv 4-(1H-indol-1yl)-1-piperidinyl derivatives
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH10204012A (ja) * 1997-01-24 1998-08-04 Daicel Chem Ind Ltd ３−ヒドロキシメチルシクロアルカノール類およびその製造方法
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
IL152719A0 (en) * 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
EP1854798A3 (de) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Kondensierte heterozyklische Succinimid-Verbindungen und Analoga daraus, Modulatoren der nuklearen Hormonrezeptorfunktion
DK1327440T5 (da) * 2000-09-22 2009-09-07 Dainippon Sumitomo Pharma Co Orale pr parater med gunstige nedbrydningsegenskaber
US20040087548A1 (en) * 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1423107B1 (de) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fettalkohol-arzneimittel-konjugate
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
HUP0500096A3 (en) * 2001-12-19 2012-08-28 Bristol Myers Squibb Co Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function, process for producing them and pharmaceutical compositions containing them
JP3977162B2 (ja) * 2002-06-21 2007-09-19 株式会社バンダイナムコゲームス キャラクタ情報管理装置、プログラム及び情報記憶媒体
EP1535616B1 (de) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Mittel zur behandlung des integrationsdysfunktionssyndroms
WO2004113333A1 (ja) * 2003-06-23 2004-12-29 Dainippon Sumitomo Pharma Co., Ltd. 老人性痴呆症治療剤
USRE45573E1 (en) 2003-07-29 2015-06-23 Sumitomo Dainippon Pharma Co., Ltd. Process for producing imide compound
KR100578104B1 (ko) * 2003-12-16 2006-05-10 한국과학기술원 코발트-질소 박막을 이용한 코발트 다이실리사이드에피층의 형성방법
WO2005080976A1 (ja) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
JP2006169154A (ja) * 2004-12-15 2006-06-29 Sumitomo Chemical Co Ltd 第四級アンモニウム塩の製造方法
JP4708012B2 (ja) * 2004-12-15 2011-06-22 大日本住友製薬株式会社 第四級アンモニウム塩の製造法
JP4799892B2 (ja) * 2005-03-31 2011-10-26 住友化学株式会社 シクロヘキサン誘導体およびその製造方法
JP4733120B2 (ja) 2005-05-26 2011-07-27 大日本住友製薬株式会社 医薬品組成物
CN101198331B (zh) * 2005-06-13 2012-05-02 大日本住友制药株式会社 增溶化制剂
MY153868A (en) * 2007-04-04 2015-03-30 Merck Sharp & Dohme Therapeutic agents
US20090076027A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
KR20100121483A (ko) 2008-02-11 2010-11-17 다이닛본 스미토모 세이야꾸 가부시끼가이샤 용출성이 개선된 정제
US20110003994A1 (en) 2009-07-02 2011-01-06 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative
US20110124659A1 (en) * 2009-11-17 2011-05-26 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative
JP5317939B2 (ja) * 2009-12-02 2013-10-16 住友化学株式会社 アルコール化合物の製造方法
WO2011093522A1 (en) * 2010-01-28 2011-08-04 Dainippon Sumitomo Pharma Co., Ltd. A cycloalkane derivative
US8735397B2 (en) * 2010-03-29 2014-05-27 Vanderbilt University Method for treating schizophrenia and related diseases
WO2011136384A1 (en) * 2010-04-26 2011-11-03 Dainippon Sumitomo Pharma Co., Ltd. A process of a quaternary ammonium salt using phosphate
EP2563790B1 (de) * 2010-04-26 2016-09-14 Sumitomo Dainippon Pharma Co., Ltd. Verfahren für ein quaternäres ammoniumsalz
WO2012053654A1 (en) * 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012123858A1 (en) 2011-03-14 2012-09-20 Ranbaxy Laboratories Limited Amorphous lurasidone hydrochloride
MX358344B (es) 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
WO2012131606A1 (en) 2011-04-01 2012-10-04 Ranbaxy Laboratories Limited Process for the preparation of an antipsychotic agent
CN102731512B (zh) * 2011-04-12 2015-04-22 天津药物研究院 一种鲁拉西酮中间体及鲁拉西酮的制备方法
WO2012156981A1 (en) 2011-05-13 2012-11-22 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
WO2013030722A1 (en) 2011-08-26 2013-03-07 Ranbaxy Laboratories Limited Crystalline lurasidone hydrochloride
CN103130794B (zh) * 2011-12-02 2016-06-22 苏州二叶制药有限公司 卢拉西酮盐酸盐的晶体a的制备方法
CN103130795A (zh) * 2011-12-02 2013-06-05 苏州二叶制药有限公司 卢拉西酮盐酸盐的晶体a及其用途
US9409899B2 (en) 2012-02-13 2016-08-09 Cadila Healthcare Limited Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates
EP2827868B8 (de) * 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit fettsäureestern
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
CN103360383B (zh) * 2012-04-11 2016-07-06 上海医药工业研究院 鲁拉西酮盐酸盐的晶型b及其制备方法
US10052319B2 (en) 2012-04-26 2018-08-21 Sumitomo Dainippon Pharma Co., Ltd. Medicament for treating mental and behavioural disorders
CN102746289B (zh) * 2012-04-28 2016-06-08 上海医药工业研究院 一种盐酸卢拉西酮的制备方法
CN103450172A (zh) * 2012-05-30 2013-12-18 广州药源生物医药科技有限公司 一种抗精神病药物鲁拉西酮的制备方法
WO2013190455A2 (en) * 2012-06-18 2013-12-27 Shasun Pharmaceuticals Limited Process for the preparation of lurasidone hydrochloride
US9580414B2 (en) * 2012-07-18 2017-02-28 Shasun Pharmaceuticals Limited Salts and hydrates of antipsychotics
WO2014037886A1 (en) 2012-09-04 2014-03-13 Ranbaxy Laboratories Limited Process for the preparation of lurasidone hydrochloride
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN102827157A (zh) * 2012-09-20 2012-12-19 北京哈三联科技股份有限公司 一种制备鲁拉西酮的方法
WO2014064714A2 (en) * 2012-10-22 2014-05-01 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of lurasidone hydrochloride
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103864774B (zh) * 2012-12-14 2016-09-28 成都弘达药业有限公司 一种鲁拉西酮的制备方法
WO2014102808A1 (en) 2012-12-25 2014-07-03 Lee Pharma Limited A process for preparation of trans (lr,2r)-cyclo hexane 1, 2-dicarboxylic acid
WO2014102834A2 (en) * 2012-12-31 2014-07-03 Hetero Research Foundation Process for lurasidone
ITMI20130262A1 (it) * 2013-02-22 2014-08-23 Edmond Pharma Srl Procedimento per la preparazione di lurasidone cloridrato
CN104031041A (zh) * 2013-03-06 2014-09-10 江苏恩华药业股份有限公司 盐酸鲁拉西酮的新晶型及其制备方法
CN104513182A (zh) * 2013-10-08 2015-04-15 无锡万全医药技术有限公司 一种(1r,2r)-1,2-环己烷二甲醇二磺酸酯的制备方法
ITMI20131737A1 (it) 2013-10-17 2015-04-18 Procos Spa Processo per la sintesi industriale di lurasidone
CZ306203B6 (cs) 2013-12-06 2016-09-29 Zentiva, K. S Způsob syntézy lurasidonu
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
JP6594351B2 (ja) 2014-06-16 2019-10-23 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
US10426770B2 (en) 2014-10-14 2019-10-01 Jubilant Generics Limited Process for the preparation of Lurasidone hydrochloride
CN106146486A (zh) * 2015-04-21 2016-11-23 上海医药集团股份有限公司 一种制备高纯度高收率鲁拉西酮的方法
EP3310785B1 (de) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepinderivate, zusammensetzungen und verfahren zur behandlung kognitiver beeinträchtigung
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110114063B (zh) 2017-01-06 2022-01-11 广东东阳光药业有限公司 鲁拉西酮固体分散体及其制备方法
EP3760205A4 (de) 2018-02-28 2021-10-27 Sumitomo Dainippon Pharma Co., Ltd. Pharmazeutische zubereitung vom typ einer wässrigen suspension
JPWO2019167978A1 (ja) 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
MX2020013927A (es) 2018-06-19 2021-03-02 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
CN113024535B (zh) 2019-12-24 2024-08-02 上海科胜药物研发有限公司 一种鲁拉西酮盐酸盐的制备方法
CN118541369A (zh) 2022-01-11 2024-08-23 苏文生命科学有限公司 杂脂环衍生物及其在治疗cns病症中的用途
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN117285530B (zh) * 2023-08-03 2026-01-16 迪嘉药业集团股份有限公司 一种盐酸鲁拉西酮新制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421900A1 (fr) * 1977-03-17 1979-11-02 Sauba Lab Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques
EP0009465A1 (de) * 1978-09-20 1980-04-02 Ciba-Geigy Ag N-(1-(4-Amino-2-chinazolinyl)-3- oder -4-piperidyl-lactame, Verfahren zu ihrer Herstellung, sowie pharmazeutische Präparate enthaltend diese Verbindungen
US4355037A (en) * 1981-11-12 1982-10-19 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidyl)-1,2-benzisoxales
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4507303A (en) * 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPS5976059A (ja) * 1982-10-21 1984-04-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
NL8401907A (nl) * 1983-06-27 1985-01-16 Sandoz Ag Spirosuccinimiden en werkwijzen voor het bereiden en toepassen van deze spirosuccinimiden.
US4590196A (en) * 1984-08-23 1986-05-20 Bristol-Myers Company Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
JPS61238784A (ja) * 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
US4656173A (en) * 1985-04-24 1987-04-07 Bristol-Myers Company Antipsychotic benzisothiazole S-oxide compound
JP2660407B2 (ja) * 1986-09-26 1997-10-08 住友製薬株式会社 新規なイミド誘導体
CA1335289C (en) * 1987-10-26 1995-04-18 Fujio Antoku Piperidinyl benzisoxazole derivatives, their production and pharmaceutical use

Also Published As

Publication number Publication date
US5532372A (en) 1996-07-02
DE69129282T4 (de) 2011-01-13
GR3026697T3 (en) 1998-07-31
US5780632A (en) 1998-07-14
EP0464846A1 (de) 1992-01-08
CA2046429A1 (en) 1992-01-07
EP0464846B1 (de) 1998-04-22
DK0464846T3 (da) 1998-11-30
JPH0517440A (ja) 1993-01-26
DE69129282T2 (de) 1998-08-20
CA2046429C (en) 2003-09-16
ES2115599T3 (es) 1998-07-01
DE69129282D1 (de) 1998-05-28
JP2800953B2 (ja) 1998-09-21

Similar Documents

Publication Publication Date Title
ATE165359T1 (de) Imidderivate, ihre herstellung und verwendung
ATE117295T1 (de) 4-oxochinolin-3-carbonsäure-derivate, ihre herstellung und ihre verwendung.
ATE82272T1 (de) Lipid-derivate, ihre herstellung und verwendung.
JPS55164678A (en) Novel cyclic imidazolecyanoguanidine
DE68905407D1 (de) Analgetische carbonsaeureamid-derivate.
FI953710A0 (fi) Uusia pyrrolokarbatsoleja
ATE95816T1 (de) 2-((4-piperidinyl)methyl>-1,2,3,4tetrahydroisochinolin-derivate, ihre herstellung und ihre therapeutische verwendung.
DE69523259D1 (de) Amine Derivate, ihre Herstellung und Anwendung
DE69017254D1 (de) N-acryloylpiperazin-Derivate, deren Herstellung und deren Verwendung als PAF-Antagonisten.
ATE71370T1 (de) 2-amino-5-hydroxy-4-pyrimidone.
DE69607890D1 (de) Aromatische Hydroxamsäure-Verbindungen, ihre Herstellung und Verwendung
ATE73759T1 (de) Fungizide.
ATE115537T1 (de) Biphenyl-5,5'-bis-alkansäurederivate, deren herstellung und verwendung.
DE69526332D1 (de) Indol-derivate
ATE198194T1 (de) Azetidinonderivate für die herstellung von carbapenemantibiotika
IT1217900B (it) Composti eterociclici azotati ad azione antifungina
TH3409A (th) อนุพันธ์ของซัคคารินที่เติมหมู่เอซิลแล้ว

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time